< previous issue
next issue >
Epstein–Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment
The Epstein–Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis
Tanner, J.E.; Alfieri, C.
Identifying the patient at risk for post-transplant lymphoproliferative disorder
Epstein–Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease
Rowe, D.T.; Webber, S.; Schauer, E.M.; Reyes, J.; Green, M.
The diverse pathology of post-transplant lymphoproliferative disorders: the importance of a standardized approach
The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation
Green, Michael; Reyes, Jorge; Webber, Steven; Rowe, David
Anti-B cell and anti-cytokine therapy for the treatment of post-transplant lymphoproliferative disorder: past, present, and future
Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder
Davis, Connie L.
Recurrent Epstein–Barr virus associated disease in a cardiac transplant patient: evolution from plasmacytic hyperplasia to diffuse large cell lymphoma
Larratt, L.M.; Hamilton, M.; Coupland, R.; Preiksaitis, J.K.